30. November 2016
Press Release: Zedira receives funding by the German Government for the development of transglutaminase inhibitors for the treatment of diabetic nephropathy
Read more | Document

30. November 2016
Pressemitteilung: Zedira erhält Fördermittel für die Entwicklung von Transglutaminase-Blockern zur Behandlung der diabetischen Nephropathie
Read more | Document

22. September 2016
Zedira supports 2nd International Factor XIII Workshop
Read more | Document

01. July 2016
Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
Read more | Document

01. July 2016
Pressemitteilung: Dr. Falk Pharma GmbH und Zedira GmbH starten klinische Phase 1b zur medikamentösen Behandlung der Zöliakie
Read more | Document

23. May 2016
Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
Read more | Document

20. April 2016
Zöliakie – weit mehr als ein bisschen Bauchschmerzen und Durchfall Von der Grundlagenforschung zur klinischen Entwicklung
Read more | Document

25. February 2016
Curious about your antibody or anti-serum?
Read more | Document

26. January 2016
Zedira supports Gordon Research Conference on "Transglutaminases in Human Disease Processes"
Read more | Document

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • MEDICA

    13.11.2017 - 16.11.2017
    Düsseldorf, Germany

  • Gordon Research Conference on: Transglutaminases in Human Disease Processes

    16.06.2018 - 17.06.2018
    Les Diablerets, Switzerland